ALXN News and Press, Alexion Pharmaceuticals Inc. From 12/08/20

The recent FDA approval of Orladeyo (Berotralstat) has completely de-risked BioCryst's future. Orladeyo has the ability to be a "blockbuster drug" and we are of the opinion that it very much has the ability to become Standard of Care. Income and a move to being FCF positive possib...

The year 2020 has truly been a roller-coaster ride for the stock market. After falling to extreme lows in mid-March as the coronavirus pandemic took hold, the market reached incredible highs on Nov. 24. The Dow Jones Industrial Average crossed the 30,000 mark for the first time ever...

Currently trading at 5-year historical PEG and PE NTM of 0.7x and 19.9x, respectively, VRTX's monopoly in cystic fibrosis is being grossly underappreciated by sell-side analysts. Long-term international expansion and pipeline opportunities represent a $4.8Bn and $9.5Bn TAM, respective...

While growth stocks have dominated in 2021, many have hit extreme valuations. That's why investors should consider growth stocks with high upside potential. Here are four worth a look: Alexion Pharmaceuticals, Inc. (ALXN), Newmont Goldcorp Corporation (NEM), Sanofi (SNY), and LKQ Corporation ...

The European Commission has granted marketing authorization to Alexion Pharmaceuticals' (ALXN) Ultomiris (ravulizumab-cwvz) 100 mg/mL intravenous formulation for the treatment of adults with paroxysmal nocturnal hemoglobinuria ((PNH)), a rare blood disease i...

– The new 100 mg/mL formulation will reduce infusion time by approximately 60%, lessening the burden on patients – – ULTOMIRIS is approved for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS) –...

Developing drugs to treat or cure rare diseases can be a lucrative line of business, as Orchard Therapeutics (NASDAQ: ORTX) and Alexion Pharmaceuticals (NASDAQ: ALXN) know. While it might seem highly limiting to target conditions that only affect a handful of patients worldw...

As the demand for a COVID-19 vaccine or a treatment is on the rise with the number of coronavirus cases increasing each passing day, Alexion Pharmaceuticals (ALXN), BioNTech (BNTX), and Ultragenyx Pharmaceutical (RARE) should benefit significantly because of the progress they made so far with...

BioCryst recently reported additional results of BCX9930 in PNH patients naïve to C5 inhibitors. The results were not perfect but seem good enough to support further development. BCX9930's value proposition goes far beyond PNH, and diseases other than PNH hold the real potent...

- Accepted abstracts include Phase 2 safety, efficacy, and tolerability data for CAEL-101 in AL amyloidosis - - Phase 3 studies of CAEL-101 in AL amyloidosis are underway - Caelum Biosciences and Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced...